Breast Cancer (Triple Negative Breast Cancer (TNBC))
Conditions
Keywords
TNBC, Breast Cancer, Warehouse, Mutanome, RNA, Vaccine
Brief summary
The Mutanome Engineered RNA Immuno-Therapy (MERIT) study introduced a novel concept for Individualized Cancer Immunotherapy (IVAC®) to treat each patient with the relevant and immunogenic RNA vaccines for a given patient's tumor. The TNBC-MERIT trial used two complementary strategies, the WAREHOUSE and the IVAC® MUTANOME concept, resulting in two custom-made IVAC® investigational medicinal products (IMPs) (IVAC\_W\_bre1\_uID and IVAC\_M\_uID) for each individual patient.
Detailed description
* The WAREHOUSE concept is based on RNA drug products shelved in a warehouse and targeting shared tumor-associated antigens (TAAs). The BioNTech Group (henceforward the "company") has identified a set of target antigens commonly expressed in TNBC. The selected breast cancer-associated antigens have been shown by immunogenicity testing to constitute suitable targets for immunotherapy and form the basis for the development of a novel RNA-based immunotherapy approach. * The IVAC® MUTANOME concept is based on the identification of tumor-specific mutations by next-generation sequencing (NGS) and on-demand RNA manufacturing for use in single patients to target multiple neo-antigens derived from mutated epitopes. The novel therapeutic concept is supported by a series of research projects and high level publications that have led to a broad acceptance that mutation-specific T cells bear enormous potential to confer anti-tumoral activity in cancer patients. * The TNBC-MERIT study introduced the novel therapeutic concept for the individualized treatment of breast cancer that is based on (i) treatment with a patient-specific liposome complexed RNA tailored to the antigen-expression profile of any given patient's tumor (WAREHOUSE immunotherapy - IVAC\_W\_bre1\_uID) and (ii) on treatment with de novo synthesized RNAs targeting up to 20 individual tumor mutations (IVAC® MUTANOME immunotherapy - IVAC\_M\_uID) following optional treatment with WAREHOUSE. The scientific rationale for the combination of the two IVAC® approaches is based on the assumption that immunotherapies that (1) acknowledge tumor heterogeneity on a single-patient level and (2) target the whole range of antigens selectively expressed on tumors ("cancer antigenome"), including immunogenic shared and unique antigens, bear the highest potential to constitute an effective treatment of tumors.
Interventions
BIOLOGICALIVAC_W_bre1_uID
vaccination
BIOLOGICALIVAC_W_bre1_uID/IVAC_M_uID
vaccination
Sponsors
BioNTech SE
Seventh Framework Programme
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed invasive adenocarcinoma triple negative breast cancer (TNBC), pT1cN0M0 - anyTanyNM0 confirmed by physical examination or imaging * Triple negative breast cancer was defined as: * HER2 negative * IHC 0-1+ * IHC 2+ and FISH negative (ratio \< 2.0 or \< 4 gene copies / cell, as per new ASCO guideline) * ER and PR negative confirmed\< 1% * For patients with surgery of primary tumor followed by adjuvant chemotherapy, treatment with IVAC\_W\_bre1\_uID was initiated after completion of the adjuvant chemotherapy. The adjuvant chemotherapy should contain anthracyclines and taxanes - except for patients with contraindications for treatment with one or both substances. * For patients with neoadjuvant chemotherapy according to local standard followed by surgery of primary tumor, treatment with IVAC\_W\_bre1\_uID was initiated after the surgery. The neoadjuvant chemotherapy should contain anthracyclines and taxanes - except for patients with contraindications for treatment with one or both substances. * Patients with planned radiotherapy (as per local policy) were eligible and should be irradiated in parallel to the vaccination cycles * Patients after completion of standard of care therapy e. g. surgery and/or chemotherapy and/or radiotherapy (as per local policy) were eligible at the discretion of the investigator after no clinical sings of recurrence and/or metastasis, if the treatment with IVAC\_W\_bre1\_uID starts within one year after completion of the radiotherapy. * Adequate organ function (hematopoietic, hepatic and renal function): * Hemoglobin ≥ 9 g/dl * ANC ≥ 1500/µl * Platelet count ≥ 100,000/mm³ * ALT/AST \<2 x ULN * Serum creatinine ≤ 1.5 ULN * Expression of at least two tumor-specific antigens of the WAREHOUSE\_bre1 confirmed by RT-qPCR on FFPE tumor tissue for ARM1 and ARM3 * Female patients, ≥ 18 years of age * Written informed consent * ECOG performance status (PS) 0-1 * Recovered pre-existing toxicities \< grade 2 according to NCI CTCAE 4.03, except alopecia * Negative pregnancy test (measured by β-HCG) for females of childbearing age * Not pregnant or nursing
Exclusion criteria
* Patients with stage pT1a,bN0M0 and anyTanyNM1disease were excluded * Patients with recurrence of breast cancer prior to the start of study treatment with IVAC\_W\_bre1\_uID * Any serious local infection (e. g. cellulitis, abscess) or systemic infection (e. g. pneumonia, septicemia, viral or fungal infection) which requires systemic treatment with antibiotics or corticoid therapy within two weeks prior to the first dose of study medication * Previous splenectomy * Concurrence of a second malignancy other than squamous or basal cell carcinoma or cervical carcinoma in situ within 5 years prior to the start of study treatment * Known hypersensitivity to the active substance or to any of the excipients * Prior solid organ transplantation or hematopoietic stem cell transplantation * Positive test for acute Hepatitis A, acute or chronic active Hepatitis B or C infection * Clinically relevant active autoimmune disease * Systemic immune suppression: * HIV disease * Use of chronic oral or systemic steroid medication (topical or inhalational steroids are permitted) * Other clinically relevant systemic immune suppression * Symptomatic congestive heart failure (NYHA 3 or 4) * Unstable angina pectoris * Adjuvant chemotherapy within 14 days before the first treatment of IVAC\_W\_bre1\_uID * Other major surgeries within 28 days before the first treatment * Other investigational agents within 28 days or 5 half-lives depending on what gives the longer range before the first treatment * Ongoing participation in another clinical study (except of Follow-Up observation) * Fertile females who were unwilling to use a highly effective method of birth control (less than 1% per year, e.g. birth control pills, injections, patches, intrauterine device, or intrauterine hormone-releasing system) during study treatment and until End of Trial visit (EOT) at day 120 * Presence of a severe concurrent illness or another condition (e. g. psychological, family, sociological, or geographical circumstances) that did not permit adequate Follow-Up and compliance with the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID | day 120 | Assessment of AEs |
| Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID plus IVAC_M_uID | up to day 246 | Assessment of AEs, End of treatment visit is depending on treatment schedule |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of induced T-cell responses for IVAC_W_bre_uID change from Visit 1 to V10 | up to 78 days | Vaccine induced T-cell responses assessed by immuno assays in peripheral blood |
| Change of induced T-cell responses for IVAC_M_uID change from Visit 18 to Follow-up Visit | up to 78 days | Vaccine induced T-cell responses assessed by immuno assays in peripheral blood |
Countries
Germany, Sweden
Contacts
STUDY_DIRECTORBioNTech Responsible Person
BioNTech SE
Outcome results
None listed